Physician profile
George Powell
NPI 1265446785
$9,107.70
in general payments reported to CMS, 2019-2025
47 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $629 · 2021: $1,513 · 2022: $898 · 2023: $1,646 · 2024: $1,657 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,103 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,103.25 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,312.84 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,198.28 | 2019-2025 | |
| Biogen, INC. | $922.81 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Emd Serono, INC. | $646.49 | 2020-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $475.98 | 2019-2024 | |
| Pfizer INC. | $382.80 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $363.11 | 2022-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $295.20 | 2020-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $289.66 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Terumo Medical Corporation | $288.85 | 2024-2025 | Metacross Otw |
| Allergan, INC. | $246.12 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $219.09 | 2021 | |
| Amgen INC. | $201.19 | 2019-2024 | Uplizna, Aimovig |
| Lundbeck LLC | $182.53 | 2021-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $178.27 | 2020-2025 | Ingrezza |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.